Holen Sie sich die Stockscreener-App
0.74
9.62%
0.0568
Schlusskurs vom Vortag:
$0.6833
Offen:
$0.72
24-Stunden-Volumen:
267.64K
Relative Volume:
0.07
Marktkapitalisierung:
$52.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.08M
KGV:
-0.343
EPS:
-2.1574
Netto-Cashflow:
$-72.06M
1W Leistung:
+4.09%
1M Leistung:
-15.82%
6M Leistung:
-50.07%
1J Leistung:
-8.55%
1-Tages-Spanne:
$0.7001
$0.7599
1-Wochen-Bereich:
$0.588
$0.7599
52-Wochen-Spanne:
$0.3234
$2.79
Io Biotech Inc Stock (IOBT) Company Profile
Firmenname
Io Biotech Inc
Sektor
Branche
Telefon
(457) 070-2980
Adresse
OLE MAALOES VEH 3, COPENHAGEN
Vergleichen Sie IOBT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
0.7281 | 48.79M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.70 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
729.43 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
462.33 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
904.45 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.81 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Io Biotech Inc Stock (IOBT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-30 | Herabstufung | TD Cowen | Buy → Hold |
Io Biotech Inc Aktie (IOBT) Neueste Nachrichten
IO Biotech (IOBT) Stock Analysis Report | Financials & Insights - Benzinga
How does IO Biotech Inc (IOBT) change from a tortoise to a hare? - Setenews
Will IO Biotech Inc. stock reach all time highs in 2025July 2025 Levels & Growth Focused Stock Reports - BỘ NỘI VỤ
Research Recommendations For IO Biotech Inc (IOBT): Here is What You Should Know - fostersleader.com
Analyst Downgrade: How IO Biotech Inc. stock benefits from strong dollarJuly 2025 Movers & Free Growth Oriented Trading Recommendations - moha.gov.vn
How strong is IO Biotech Inc. stock balance sheetMarket Performance Recap & Long-Term Safe Investment Plans - BỘ NỘI VỤ
Aug Wrap: What margin trends mean for IO Biotech Inc. stockJuly 2025 Decliners & Real-Time Volume Analysis Alerts - BỘ NỘI VỤ
IO Biotech Announces Participation in Upcoming December Investor Conferences - The Manila Times
IO Biotech (Nasdaq: IOBT) to Join Evercore, Piper Sandler December Investor Events - Stock Titan
IOBTRemeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For - mx.advfn.com
It makes sense and dollars to buy IO Biotech Inc (IOBT) stock - Setenews
IO Biotech (NASDAQ:IOBT) Stock Rating Upgraded by Wall Street Zen - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) and IO Biotech (NASDAQ:IOBT) Financial Review - Defense World
IO Biotech announces resignation of chief accounting officer and new appointment - Investing.com Australia
IO Biotech Announces Resignation of Chief Accounting Officer - MSN
IO Biotech announces resignation of chief accounting officer and new appointment By Investing.com - Investing.com South Africa
IO Biotech Announces Management Changes - TradingView
[8-K] IO Biotech, Inc. Reports Material Event | IOBT SEC FilingForm 8-K - Stock Titan
IO Biotech, Inc. Announces Executive Changes - MarketScreener
Can IO Biotech Inc. stock withstand economic slowdown2025 Retail Activity & Risk Controlled Daily Trade Plans - newser.com
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For - The Spec
Piper Sandler reiterates Overweight rating on IO Biotech stock By Investing.com - Investing.com South Africa
Is IO Biotech Inc. stock entering bullish territoryJuly 2025 Review & Fast Gaining Stock Reports - newser.com
Is IO Biotech Inc. stock a top momentum playWeekly Stock Analysis & Daily Price Action Insights - newser.com
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why - Yahoo Finance
Will IO Biotech Inc. stock deliver long term returns2025 Support & Resistance & High Conviction Buy Zone Picks - newser.com
Piper Sandler reiterates Overweight rating on IO Biotech stock - Investing.com India
IO Biotech Inc. (IOBT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is IO Biotech Inc. stock safe for conservative investorsPortfolio Return Summary & Reliable Volume Spike Alerts - newser.com
IO Biotech’s Q3 2025: Progress in Cancer Vaccine Trials - MSN
IO Biotech Presents at Jefferies Global Healthcare Conference - MSN
IO Biotech Inc (IOBT) is looking forward to a strong quarter - Setenews
IO Biotech, Inc. Updates on Cylembio Phase 3 Trial Results - TradingView
Will IO Biotech Inc. see short term momentum2025 Top Gainers & Technical Confirmation Trade Alerts - newser.com
Sector ETF performance correlation with IO Biotech Inc.Market Trend Review & Smart Allocation Stock Reports - newser.com
Is IO Biotech Inc. meeting your algorithmic filter criteriaEarnings Miss & High Conviction Investment Ideas - newser.com
What moving averages say about IO Biotech Inc.Stock Surge & Low Risk High Reward Trade Ideas - newser.com
IO Biotech’s Hold Rating Amid Financial and Regulatory Uncertainty - TipRanks
Will IO Biotech Inc. stock outperform tech sector in 2025Bull Run & Weekly High Momentum Picks - newser.com
IO Biotech, Inc.Common Stock (Nasdaq:IOBT) Detailed Stock Data | PRN_FinancialWrapper | PR Newswire - Markets Financial Content
Will IO Biotech Inc. stock benefit from green energy trendsWeekly Volume Report & Free Risk Controlled Daily Trade Plans - Fundação Cultural do Pará
IO Biotech, Inc. SEC 10-Q Report - TradingView
IO Biotech reports $8.4 mln Q3 net loss - MarketScreener
IO Biotech Reports Phase 3 Clinical Trial Data for Cylembio in Advanced Melanoma and Third Quarter 2025 Financial Results - Quiver Quantitative
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights - The Manila Times
Finanzdaten der Io Biotech Inc-Aktie (IOBT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):